3D Bioprinting Market - Global Opportunity Analysis and Industry Forecast (2023-2030)
Meticulous Research®—a leading global market research company, published a research
report titled, ‘3D Bioprinting Market by Product (Bioprinter [Extrusion, Laser,
SLA, FDM, SLS], Bioinks, Materials [Hydrogels, Cells, Biomaterials], Software,
Accessories) Application (Cancer Research, Tissue Engineering, Drug Discovery)
End User - Global Forecast to 2030.’
According
to this latest publication from Meticulous Research®, the 3D bioprinting market is projected to reach $5.21 billion by
2030, at a CAGR of 17.1% during the forecast period. The field of 3D
bioprinting has seen remarkable technological advancements, enabling
applications ranging from the creation of epidermal layers to the fabrication
of tissues and organs, including liver models for studying diseases and cancer
treatments. The development of functional tissues is among the many medical
applications made feasible by these innovations. One significant advancement in
the field of 3D bioprinting is its potential use for drug screening and
clinical trials, which holds promise for reducing reliance on animal testing.
The growth
of this market is driven by factors such as technological advancements in 3D
bioprinting, the rising geriatric population coupled with the growing burden of
chronic diseases, and increasing R&D investments. Additionally, the
increasing demand for organ transplantation is expected to offer significant
market growth opportunities.
However,
the lack of skilled professionals and the high costs associated with 3D
bioprinting restrain the growth of this market. Additionally, concerns
regarding intellectual property rights and safety issues associated with the
use of 3D bioprinted products are some of the challenges impeding the market's
growth.
Key Players
The key
players operating in the 3D bioprinting market are Organovo Holdings Inc.
(U.S.), BICO Group AB (Sweden), Aspect Biosystems Ltd. (Canada), Cyfuse
Biomedical K.K. (Japan), Advanced Solutions Life Sciences, LLC (U.S.),
CollPlant Biotechnologies Ltd. (Israel), regenHU Ltd. (Switzerland), Poietis
(France), REGEMAT 3D, SL (Spain), 3DBio Therapeutics (U.S.), and Foldink Life
Science Technologies (Armenia).
3D Bioprinting Market: Future Outlook
The 3D
bioprinting market is segmented based on Product (Bioprinters [Inkjet-based,
Extrusion-based, Stereolithography (SLA), Laser-based, Fused-deposition
modeling (FDM), Selective laser sintering (SLS), and Other Technologies],
Bioinks [Natural, Synthetic, Hybrid], Materials [Hydrogels, Extracellular
Matrices, Living Cells, Biomaterials, Other Materials], Software, Accessories,
and Consumables), Application (Cancer Research, Regenerative Medicines, Drug
Discovery and Testing, Tissue Engineering, Biomaterials and cells research,
Other Applications), End User (Pharmaceutical and Biotechnology Companies,
Academic and Research Institutes, Contract Research Organizations (CROs)), and
Geography. The study also evaluates industry competitors and analyzes the regional
and country-level markets. The study also evaluates industry competitors and
analyzes the regional and country-level markets.
Based on product, the 3D
bioprinting market is segmented into bioprinters, bioinks, materials, software,
accessories, and consumables. In 2023, the bioprinters segment is expected to
account for the largest share of the 3D bioprinting market. The large market
share of this segment is attributed to technological advancements in 3D
bioprinting, growing demand for organ transplantation due to organ failure, and
improved post-transplant outcomes. Additionally, the high adoption of
inkjet-based printing in the research field and the increasing demand for
higher durability of the structures contribute to the large market share of
this segment.
Based on application, the 3D bioprinting
market is segmented into cancer research, regenerative medicines, drug
discovery and testing, tissue engineering, biomaterials and cell research, and
other applications. In 2023, the cancer research segment is expected to account
for the largest share of the 3D bioprinting market. The large market share of
this segment is attributed to the increasing cancer research funding and
developments in 3D bioprinting technology to create three-dimensional tissue
that constructs and replicates the distinctive characteristics of cancers. This
can support cancer medication screening and assist researchers in understanding
cancer better.
Based on end user, the 3D bioprinting
market is segmented into pharmaceutical and biotechnology companies, academic
and research institutes, and contract research organizations (CROs). In 2023,
the pharmaceutical and biotechnology companies segment is expected to account for
the largest share of the 3D bioprinting market. The large market share of this
segment can be attributed to various technological advancements in 3D
bioprinting that help pharmaceutical and biotechnology industries improve
precision medicine and drug testing and increase new product launches of 3D
bioprinters and bioinks. For instance, in July 2023, CD Bioparticles (U.S.)
launched a new line of bioinks for 3D bioprinting. The new bioinks are
biocompatible and highly adaptable, which makes them perfect for a variety of
uses, such as tissue engineering, medicine delivery, and the creation and
development of 3D biological models.
Geographic Review
This
research report analyzes major geographies and provides a comprehensive
analysis of North America (U.S., Canada), Europe (Germany, France, Italy, U.K.,
Spain, Belgium, Switzerland, Netherlands, and Rest of Europe), Asia-Pacific
(China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), Latin
America (Brazil, Mexico, and Rest of Latin America), Middle East & Africa.
In 2023, North America is expected to account for the largest share of the 3D
bioprinting market, followed by Europe and Asia-Pacific. Furthermore, in 2023,
the U.S. is expected to be the largest market shareholder in North America.
North America’s major market share is attributed to the highly developed
healthcare infrastructure and the presence of major market players such as
Organovo Holdings Inc. (U.S.) and BICO Group AB (Sweden).
Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5746
Key questions answered in the report:
· Which are
the high-growth market segments in terms of product, application, end user, and
region/country?
· What was
the historical market size for 3D bioprinting across the globe?
· What are
the market forecasts and estimates for 2023–2030?
· What are
the major drivers, restraints, and opportunities in the global 3D bioprinting
market?
· Who are the
major players in the global 3D bioprinting market?
· What is the
competitive landscape like, and who are the market leaders in the global 3D
bioprinting market?
· What are
the recent developments in the 3D bioprinting market?
· What
strategies are adopted by the major players in the 3D bioprinting market?
· What are
the geographical trends and high-growth regions/countries?
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment